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The increasing number of multidrug-resistant bacteria intensifies the need to develop
new antimicrobial agents. Endolysins are bacteriophage-derived enzymes that degrade
the bacterial cell wall and hold promise as a new class of highly specific and versatile
antimicrobials. One major limitation to the therapeutic use of endolysins is their
often short serum circulation half-life, mostly due to kidney excretion and lysosomal
degradation. One strategy to increase the half-life of protein drugs is fusion to the
albumin-binding domain (ABD). By high-affinity binding to serum albumin, ABD creates
a complex with large hydrodynamic volume, reducing kidney excretion and lysosomal
degradation. The aim of this study was to investigate the in vitro antibacterial activity
and in vivo biodistribution and half-life of an engineered variant of the Staphylococcus
aureus phage endolysin LysK. The ABD sequence was introduced at different positions
within the enzyme, and lytic activity of each variant was determined in vitro and ex vivo in
human serum. Half-life and biodistribution were assessed in vivo by intravenous injection
of europium-labeled proteins into C57BL/6 wild-type mice. Our data demonstrates that
fusion of the endolysin to ABD improves its serum circulation half-life and reduces its
deposition in the kidneys in vivo. The most active construct reduced S. aureus counts
in human serum ex vivo by 3 logs within 60 min. We conclude that ABD fusions provide
an effective strategy to extend the half-life of antibacterial enzymes, supporting their
therapeutic potential for treatment of systemic bacterial infections.
Keywords: staphylococci, antibiotic alternatives, biodistribution, half-life, endolysin, albumin binding domain
(ABD), LysK, bacteriophage
INTRODUCTION
The important human pathogen Staphylococcus aureus has acquired various antibiotic resistances
over the years. Of particular importance are methicillin-resistant (MRSA) and vancomycin-
resistant S. aureus (VRSA) (Chambers and Deleo, 2010).
In order to impede this development, new antimicrobials with alternative mechanisms of action
and a reduced chance of resistance development are needed. Endolysins are bacteriophage-derived
enzymes (peptidoglycan hydrolases, PGHs) with the ability to degrade the peptidoglycan of the
bacterial cell wall, thereby causing cell death (Schmelcher et al., 2012).
The most important advantages of endolysins as antimicrobials compared to conventional
antibiotics include their rapid killing kinetics, reduced risk of bacterial resistance (Spratt, 1994;
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Schmelcher et al., 2012), and the high specificity for their
target bacteria, leaving commensal and possibly beneficial
microorganisms unaffected (Schmelcher et al., 2012).
LysK, the endolysin of the staphylococcal phage K, is an
example of a well-characterized PGH active against staphylococci
(O’Flaherty et al., 2005). The modular structure of LysK
(O’Flaherty et al., 2004) consists of a C-terminal SH3b cell wall
binding domain (CBD) (Whisstock and James, 1999), and two
enzymatically active domains (EADs): an N-terminal cysteine,
histidine-dependent amidohydrolase/peptidase (CHAP) domain
(Bateman and Rawlings, 2003), and a centrally located amidase-2
(N-acetylmuramoyl L-alanine amidase). It has been shown that
LysK maintains its high activity even if lacking the amidase-2
domain (Becker et al., 2009), and the CHAP domain has been
shown to have high activity on its own (Horgan et al., 2009).
The strong anti-staphylococcal activity of LysK and its
engineered variants has been demonstrated both in vitro and
in vivo (Kokai-Kun et al., 2007; Rashel et al., 2007; Daniel et al.,
2010; Fenton et al., 2010; Gu et al., 2011; Jun et al., 2013;
Schmelcher et al., 2014). However, despite some encouraging
results with this and other endolysins (Haddad Kashani et al.,
2017), systemic administration of most protein-based drugs,
including endolysins, is currently hampered by their short
serum circulation half-life (Loeﬄer et al., 2003; Walsh et al.,
2003). The decline in drug concentration is characterized by
alpha and beta phase decay. After intravenous administration,
concentrations decline rapidly as the drug is distributed into the
tissues and organs (Lobo et al., 2004). Subsequently, the residual
concentration decreases due to inactivation by antibodies (Jawa
et al., 2013), degradation by proteases, endocytosis by epithelial
cells, and kidney excretion (Werle and Bernkop-Schnürch, 2006).
Various approaches may extend the half-life of proteins (Patel
and Benfield, 1996; Matthews et al., 2008; Kontermann, 2011).
A promising strategy is fusion of the albumin binding domain
(ABD) to the protein of interest (Nygren et al., 1991). ABD
binds to serum albumin with strong affinity and forms a complex
with a large hydrodynamic volume, avoiding glomerular filtration
(Jonsson et al., 2008). Moreover, proteins fused to ABD are
indirectly recycled by the FcRn (Chaudhury et al., 2003). Human
serum albumin (HSA) has a serum circulation half-life of 3 weeks
in humans (Doweiko and Nompleggi, 1991), whereas murine
serum albumin (MSA) has a half-life of 35 h in mice (Chaudhury
et al., 2003). Proteins recruiting albumin through high-affinity
ABDs have been reported to show similar half-lives (Seijsing et al.,
2014).
In this study, we investigated the bacteriolytic activity, serum
circulation half-life and biodistribution of engineered variants of
the endolysin LysK, with and without ABD.
MATERIALS AND METHODS
Plasmid and DNA Construct Design
Gene synthesis and subcloning into the pET21a(+) vector
(Novagen, Darmstadt, Germany) were performed by BioBasic
Inc. (Markham, ON, Canada), and modifications resulting
in LysK variants without Amidase-2 domain and Lys6-tag
were performed in-house using standard molecular cloning
techniques (Green and Sambrook, 2012). Schematics of all
created constructs, with the corresponding names and acronyms
are presented in Figure 1. The ABD used in this study (ABD035)
is an affinity-matured variant (Jonsson et al., 2008) from
streptococcal protein G (Nygren et al., 1991; Johansson et al.,
2002).
Recombinant Protein Expression and
Purification
Vectors encoding target proteins were introduced into BL21
Gold (DE3) E. coli cells (Stratagene, La Jolla, CA, United States)
(Table 1) by electroporation. Cells were grown at 37◦C and
220 RPM in LB-PE medium (15 g/L Tryptone, 8 g/L Yeast
extract, 5 g/L NaCl, pH 7.8) supplemented with 100 µg/mL
ampicillin until OD600 reached 0.5. Protein expression
was induced by adding 0.5 mM IPTG, and cultivation
was continued over night at 19◦C and 120 RPM. Cells
were pelleted using centrifugation and disrupted using
both a Stansted Fluid Power Pressure Cell Homogenizer
(100 MPa) and sonication on ice/ethanol slurry with a
Bandelin Sonopuls HD 2076 (2 min, 1:1 pulses, 50% power).
Proteins were purified from cleared crude extracts using
nickel affinity chromatography. For the in vivo study, the
following modifications were made to reduce endotoxin
concentrations. Vectors were transformed into electrocompetent
E. coli ClearColi BL21(DE3) (Lucigen, Middleton, WI,
United States) (Table 1). LB-PES (15 g/L Tryptone, 8 g/L
yeast extract, 10 g/L NaCl, pH 7.8) medium was used for all
cultivations. Bacteria were lysed by sonication only. During
purification, the columns were washed twice with 25 ml of
ice cold lysis buffer supplemented with 0.1% Triton X-114
(Reichelt et al., 2006), and subsequently 25 ml of lysis buffer.
Proteins were tested for endotoxins using the EndoZyme kit
(Hyglos, Regensburg, Germany) according to manufacturer’s
instructions.
Europium Labeling
Europium labeling of proteins via the Eu-chelator complex
(Sodium[4′-(4′-Amino-4-biphenylyl)-2,2′:6′,2′′-terpyridine-6,6′′-
diylbis(methyliminodiacetato)]europate(III)) was performed by
BioTeZ (Berlin, Germany).
Surface Plasmon Resonance
For measuring binding of ABD-containing constructs to HSA by
surface plasmon resonance (SPR), a Biacore X (GE Healthcare,
Uppsala, Sweden) with a C1 sensor chip and HBS-T running
buffer was used essentially as previously described (Jonsson et al.,
2008).
Human serum albumin (HSA; 100 µg/ml) was immobilized
in flow cell 2 using an Amine Coupling Kit (GE Healthcare,
Uppsala, Sweden) according to the manufacturer’s instructions.
For interaction analysis, 30 µl of endolysin construct at a
concentration of 50 nM was injected, with flow cell 1 serving
as the reference. The chip surface was regenerated using 15 mM
HCl.
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FIGURE 1 | Schematic representation of the DNA constructs created in this study. The DNA constructs contain the genes for the EADs CHAP and amidase-2, the
CBD SH3b, a Lys6-tag (gray) for labeling with europium (Eu) via amine coupling, a His6-tag for IMAC purification and the ABD for serum circulation half-life
extension. In some constructs, the amidase-2 domain and/or Lys6-tag was removed and the ABD inserted using restriction sites included in the engineered
full-length LysK construct CASL. The figure was made using Illustrator for Biological Sequences (IBS) (Liu et al., 2015).
TABLE 1 | Bacterial strains used in this study.
Strain Source Reference
Staphylococcus aureus SA113 (ATCC 35556) Andreas Peschel, University of Tübingen, Germany (Kristian et al., 2004)
S. aureus Newman D2C (ATCC 25904) Brigitte Berger-Bächi, University of Zurich, Switzerland (Bischoff et al., 2004)
E. coli BL21-Gold(DE3) Stratagene, La Jolla, CA, United States
E. coli ClearColi BL21(DE3) Lucigen, Middleton, WI, United States
Turbidity Reduction Assay
The assay was performed essentially as described before
(Schmelcher et al., 2014), using S. aureus SA113 (Kristian
et al., 2004) (Table 1) and PBS supplemented with 5 µM
HSA (PBS-HSA). Specific enzymatic activity was expressed as
1OD600min−1µM−1. For comparison of specific activities, one-
way ANOVA was performed. The impact of Lys6-tags on activity
was assessed by an unpaired t-test (GraphPad Prism, 7.02).
Time Kill Assay
For the time kill assay, S. aureus Newman (Bischoff et al.,
2004) (Table 1) was grown in LB medium to an OD600 of 0.5,
and the assay was performed essentially as previously described
(Schuch et al., 1986). Target bacteria at a concentration of
106 CFU/ml were mixed with 200 nM of endolysin in human
serum (H4522, Sigma-Aldrich, St Louis, MO, United States).
Human serum alone was used as negative control. For statistical
analysis, two-way ANOVA on log-transformed data followed by
Sidak’s multiple comparisons test (GraphPad Prism, 7.02) was
performed.
In vivo Half-Life and Biodistribution
Study
Eight to ten weeks old female C57BL/6 wild-type mice (Janvier,
Le Genest St. Isle, France) were separated into two groups of
four mice each. Animals were injected intravenously into the
tail vein with ∼7 nmol/kg body weight (100 µl, 1.4 µM) of Eu-
labeled C[ABD]SL[Eu] or the control CSL[Eu]. Blood was drawn
from the tail vein after 0.25, 24, 72, 120, and 144 h. Heparinized
blood was centrifuged and plasma was collected. Mice were
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euthanized at 144 or 216 h, and organs were homogenized using
a TissueLyser (Qiagen, Valencia, CA, United States) in PBS (1:1
weight/volume ratio). The Europium content in the blood and
organ samples was determined using an Infinite M1000 PRO
(Tecan, Durham, NC, United States) time-resolved fluorescence
plate reader. Obtained values were correlated to a spiked standard
dilution series of respective proteins in mouse serum or a
homogenate of respective organs.
Serum concentrations were plotted against time, and the four
last values were used to calculate the beta half-life of the protein
using a one phase decay model in Prism (GraphPad Software, San
Diego, CA, United States). Student’s t-test was used to compare
protein concentrations in the serum at the last time point at
144 h. For comparing protein concentrations in organ samples,
a two-way ANOVA on log-transformed data followed by Sidak’s
multiple comparisons test was performed.
Results
Design and Production of Peptidoglycan
Hydrolase Constructs
A high affinity variant of ABD [ABD035 (Jonsson et al., 2008)]
was selected for fusion to full length and shortened versions of the
LysK endolysin. The shortened versions feature a deletion of the
centrally located amidase-2 domain, since this domain reportedly
contributes little to the overall activity of the enzyme (Becker
et al., 2009). Different variants of LysK-ABD fusion constructs
were created, with the ABD inserted at various positions within
the proteins (Figure 1), in an effort to identify the ABD-tagged
version with the highest staphylolytic activity.
All constructs featured a C-terminally located His6-tag
to allow purification by immobilized metal ion affinity
chromatography (IMAC). In order to allow for directed
europium (Eu) labeling, all constructs generated in the first
round of cloning contained a Lys6-tag upstream of the His6-tag,
thereby reducing the risk of compromising activity by the labeling
process. Eu labeling was used to measure the concentration of the
proteins in blood and organs using time-resolved fluorescence.
Protein identity and purity of protein preparations were
controlled by SDS–PAGE (Supplementary Figure S1A).
A prominent additional band of lower than expected molecular
weight was observed for all engineered constructs containing the
amidase-2 domain, whereas this band was not detected in the
parental LysK-His6. Consequently, all constructs yielding the
observed truncated protein product were excluded from further
experiments.
High-Affinity Albumin Binding Domain
(ABD) Mediates Binding of Peptidoglycan
Hydrolase Constructs to Human Serum
Albumin
The selected fusion constructs were investigated for their ability
to bind to HSA using surface plasmon resonance analysis. HSA
was immobilized on the surface of a sensor chip, and interaction
of fusion proteins in solution with the immobilized HSA was
monitored in real-time. All three protein constructs containing
an ABD showed strong binding to HSA, whereas the non-
ABD containing control showed weak binding (Supplementary
Figure S2). These results suggest that the ABD retains its
functionality within the context of the fusion proteins.
ABD-Containing Constructs Retain
Bacteriolytic Activity in vitro
The in vitro lytic activity of the selected protein constructs was
determined by a turbidity reduction assay, which measures the
reduction in optical density of a bacterial suspension over time
in response to different concentrations of endolysin. The assay
was performed in PBS-HSA in order to account for any possible
inhibition caused by steric hindrance upon binding of the ABD-
containing endolysin constructs to HSA. The most active ABD-
containing construct, C[ABD]SL, displayed an activity of 0.54
1OD600 min−1 µM−1 (compared to 2.94 1OD600 min−1
µM−1 for the parental enzyme CSL; Figure 2A) and was selected
for further evaluation in vitro and in vivo.
As a next step, Lys6-tag-free variants of C[ABD]SL and the
control CSL were generated, yielding the constructs CHAP-ABD-
SH3b-His6 (C[ABD]S) and CHAP-SH3b-His6 (CS), respectively
(Figure 1). Lys6-tags had been added to all original constructs
to facilitate Eu labeling for in vivo experiments. However, they
would not be included in enzymes used therapeutically. The Lys6-
free constructs showed higher activity in the turbidity reduction
assay compared to their tagged counterparts (Figure 2B),
for which reason they were chosen for further in vitro
analysis.
To investigate the influence of HSA on the activity of the
control CS and C[ABD]S, both enzymes were compared in
turbidity reduction assays performed in PBS only and PBS-HSA.
In the presence of HSA, the activity of CS increased slightly as
compared to PBS alone (Figure 2C). The reason for this may
be that an excess of HSA reduces unspecific binding of the
enzyme to the polystyrene of the 96-well plate, increasing the
effective concentration of the endolysin construct in the solution.
In contrast, the activity of the C[ABD]S construct decreased upon
addition of HSA (Figure 2D). It is likely that the HSA binding
causes steric hindrance impeding the activity of the endolysin
construct or affecting the diffusion rate through the increased size
of the complex.
In order to determine the staphylolytic activity of C[ABD]S
and CS in an environment mimicking bacteremia, a time-kill
assay with the selected constructs in human serum and the
clinical isolate S. aureus Newman was conducted. Although the
ABD-containing construct was less effective than the control
enzyme in this experiment, it reduced the number of CFUs by
approximately 3 log units within 60 min at a concentration of
200 nM (compared to 4 log units for the control) (Figure 3).
An Intramolecular ABD Increases the
Serum Circulation Half-Life of
C[ABD]SL[Eu] in Mice
The Lys6-tagged constructs C[ABD]SL and CSL were selected
for investigating the effect of an intramolecular ABD on the
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FIGURE 2 | In vitro analysis of PGH constructs with and without ABDs by turbidity reduction assays. Staphylococcus aureus SA113 substrate cells were mixed with
indicated concentrations of endolysin constructs. The reduction in optical density over time was analyzed and the specific activity was calculated as
1OD600/(min∗µM). (A) Comparison of the specific activities of the control PGH construct CSL and its ABD-containing derivatives. The experiment was performed in
PBS-HSA. (B) Effect of the removal of Lys6-tags from CSL and its most active ABD-containing derivative. The experiment was performed in PBS-HSA. (C,D)
Turbidity reduction assays comparing the activity of CS (C) and C[ABD]S (D) at 125 nM concentration in PBS and PBS-HSA. Data were control-corrected and
normalized. Error bars represent the standard error of the mean from 3 (A,B) and 4 (C,D) individual experiments. ∗p < 0.05; ∗∗p < 0.01; ns, non-significant.
serum circulation half-life of these proteins in mice. To this end,
preparations of both proteins of high purity (Supplementary
Figure S1B) and with endotoxin concentrations <0.05 EU/ml
were labeled with the lanthanide europium (Eu) in order to
enable measurement of protein concentrations in murine blood
and organs by time-resolved fluorescence.
The Eu-labeled ABD-containing protein CHAP-ABD-
SH3b-Lys6[Eu]-His6 (C[ABD]SL[Eu]) and the control
CHAP-SH3b-Lys6[Eu]-His6 (CSL[Eu]) were injected
intravenously into C57BL/6 wild-type mice. The blood was
sampled at predetermined time points and analyzed for target
protein concentrations via time-resolved fluorescence. As
previously described for other proteins (Wang et al., 2008;
Seijsing et al., 2014), concentrations of both the ABD-containing
construct and the control decreased over time following
a biphasic process (Figure 4A). During the alpha phase,
both concentrations decreased at approximately the same rate
(approximately 2 log units within 24 h). However, during the beta
phase, the ABD-containing protein showed a slower decrease in
concentration than the control. After 144 h, the C[ABD]SL[Eu]
concentration in the blood was 16-fold higher than that of the
control construct, which was statistically significant (p < 0.05).
From these data, the serum circulation half-life was calculated to
be 23 h for the control CSL[Eu] and 34 h for the ABD-containing
C[ABD]SL[Eu].
ABD Prevents Endolysin Kidney
Deposition
In addition to determining the half-life of both constructs in
the blood, their biodistribution was investigated by measuring
the concentrations of Eu-labeled proteins in various organs of
the mice. Mice were euthanized and organs were harvested 144
or 216 h post-injection. Europium was found to accumulate
in liver and kidneys over time, with the control CSL[Eu]
yielding higher concentrations in both organs and at both time
points than the ABD-containing C[ABD]SL[Eu]. This effect
was statistically significant in the kidneys and was strongly
pronounced at 216 h, where the difference between the constructs
was more than 150-fold (Figure 4B). Protein concentrations in
the spleen, lung, and heart were below the detection limit for both
proteins.
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FIGURE 3 | Time kill assay comparing the antibacterial activities of CS and
C[ABD]S. S. aureus Newman bacteria were mixed with 200 nM of both PGHs
in human serum. Serial dilutions of the mixtures were plated at predetermined
time points, and colonies were counted after over-night incubation. Data are
shown as mean viable bacterial concentrations with error bars representing
standard errors of the means from four individual experiments with technical
duplicates each. ∗p < 0.05; ∗∗∗∗p < 0.0001.
DISCUSSION
Therapeutic efficacy of a protein-based drug depends on several
factors including activity in vivo, bioavailability at the site
of infection, immunogenicity, and serum circulation half-life.
Successful eradication of an infection can be achieved only if
the local concentration of the therapeutic antimicrobial agent
remains high enough over a sufficient period of time in order to
kill the majority of bacteria. In this respect, an extended serum
circulation half-life is considered advantageous, since it avoids the
necessity of repeated or continuous administration (Walsh et al.,
2003; Resch et al., 2011b).
The serum circulation half-lives of PGHs reported in the
literature to date are short, ranging from 20.5 min to 1 h (Loeﬄer
et al., 2003; Walsh et al., 2003; Jun et al., 2017). Efforts to
extend the half-life of PGHs have been pursued, using PEGylation
(Walsh et al., 2003; Resch et al., 2011b) or dimerization (Resch
et al., 2011a). By conjugating a polyethylene glycol (PEG)
polymer chain to a protein, its hydrodynamic volume increases,
which reduces glomerular filtration in the kidneys. In addition,
PEGylation can decrease immunogenicity if potential epitopes
on the molecule are masked from the immune system (Veronese
and Mero, 2008). Unfortunately, the introduction of bulky
structures such as PEG has been found to severely affect and even
inactivate enzymatic activity of endolysins (Resch et al., 2011b).
Moreover, PEGylation is a cumbersome process that may result
in multidisperse products, and anti-PEG antibodies have been
observed in exposed patients, in addition to non-degraded PEG
deposited in patients’ livers (Knop et al., 2010).
An enzyme dimerization strategy has been used with the
pneumococcal phage endolysin Cpl-1 (Resch et al., 2011a). In
this case, monomeric endolysin molecules were dimerized by
introduction of specific cysteine residues, which resulted in a 10-
fold decrease in plasma clearance rate. However, this strategy may
be successful only for endolysins which exhibit a natural tendency
to dimerize, as suggested for Cpl-1 by the authors of the study.
FIGURE 4 | Normalized mean serum concentration-time profiles and
biodistribution in murine liver and kidneys of CSL[Eu] and C[ABD]SL[Eu].
C57BL/6 wild-type mice were injected intravenously with the europium
(Eu)-labeled protein constructs, blood samples were drawn at predetermined
time points, and organs were harvested after euthanasia at 144 and 216 h
post-injection. Blood and organs were analyzed for Eu concentration and data
are shown as mean concentrations with standard errors of the mean from a
total of four mice per group. (A) Normalized concentrations of Eu-labeled
endolysin constructs in the murine blood at various time points from 0 to
144 h post-injection. (B) Eu concentration of the control CSL[Eu] and the
ABD-containing C[ABD]SL[Eu] in the liver and kidneys 144 and 216 h
post-injection.
Fusion of endolysins with ABD is a straightforward process
that requires no posttranslational chemical modifications. The
ABD can be iterated at different positions in the protein until
a suitable construct is identified. Clearly, targeted modification
represents a major advantage over biochemical approaches as
compared to PEGylation, which always result in a heterogeneous
mix of products. Not only does the ABD-HSA complex give
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an increased hydrodynamic volume reducing kidney excretion
but, as opposed to PEGylated proteins, it is also rescued
from lysosomal degradation through recycling by the neonatal
Fc receptor (FcRn) (Chaudhury et al., 2003). Furthermore,
recombinant proteins are, unlike PEG, eventually degraded
without leaving any chemical traces in the body.
Since endolysins are foreign to the body, they can be
immunogenic, as previously reported (Loeﬄer et al., 2003;
Fischetti, 2010; Schmelcher et al., 2012). It can be speculated
that the ABD may indirectly dampen such a response. Since
ABD fusion proteins form complexes with HSA in the blood,
they are recycled back into the blood circulation by the FcRn
when endocytosed by epithelial cells or antigen-presenting
cells (Chaudhury et al., 2003). Thereby, fusion of ABD to
the protein circumvents lysosomal degradation, which would
otherwise lead to presentation of immunogenic epitopes by
the major histocompatibility complex (MHC) and induce long-
lasting B-cell mediated humoral immune response (Bryant and
Ploegh, 2004).
In this study, we observed a relatively long half-life of 23 h
in mice for the 35 kDa parental enzyme CSL[Eu], which was
surprising given the previously published values.
A two- or multi-domain endolysin is likely to show a longer
half-life than a globular protein with the same molecular weight
due to its larger hydrodynamic volume. However, both Cpl-
1 and lysostaphin are also two-domain modular proteins, with
half-lives of 20.5 min (Loeﬄer et al., 2003) and less than 1 h
(Walsh et al., 2003), respectively. In addition, the high pI
of CSL (9.83) gives the protein a strong positive net charge,
possibly resulting in attraction to negatively charged cells and
tissues, thus delaying clearance. Such a hypothesis could be
sustained considering the low pI of Cpl-1 (Loeﬄer et al., 2003).
However, the pI of lysostaphin is similar, which suggests that
the clearance mechanism also depends on other factors (Loeﬄer
et al., 2003; Walsh et al., 2003). The difference in half-life between
lysostaphin and the LysK-derivative CSL may also be explained
by the different functions of these two enzymes. Lysostaphin is a
bacteriocin acting from the outside, therefore relying on efficient
diffusion. Thus, it can be reasoned that this protein has been
optimized by evolution to minimize interactions with molecules
in the environment, which may explain its rapid clearance. In
contrast, LysK is a phage endolysin accessing the peptidoglycan
from within. Free diffusion through the environment following
bacterial lysis would be disadvantageous for the phage, due to the
risk of harming not yet infected neighboring hosts (Verbree et al.,
2017).
The SAL200 compound is a recombinant version of the
staphylococcal endolysin SAL-1 highly similar to LysK. The
in vivo serum circulation half-life of SAL200 was relatively
long when tested in monkeys, ranging from 0.3 to 9.7 h (Jun
et al., 2016). However, a recent clinical trial with SAL200
demonstrated a very short serum circulation half-life of only
0.04 to 0.38 h in humans (Jun et al., 2017). This indicates
a large discrepancy in the drug’s pharmacokinetics between
different organisms, and suggests that the long in vivo serum
circulation half-life of CSL[Eu] in mice may not be extrapolated
to other systems. Here, introduction of an ABD into the CSL
protein resulted in a significant increase in serum circulation
half-life in mice. The protein construct containing the high-
affinity ABD035 showed a half-life of 34 h, which is in line
with what has been reported for other ABD fusion proteins
previously (Chaudhury et al., 2003; Orlova et al., 2013; Seijsing
et al., 2014).
From the biodistribution data, it is evident that the ABD-
containing construct C[ABD]SL[Eu] is superior to the non-ABD-
containing control in avoiding kidney deposition. As discussed
above, this is likely an effect of the differences in hydrodynamic
volume and to a smaller extent FcRn recycling (Chaudhury
et al., 2003; Roopenian and Akilesh, 2007; Akilesh et al., 2008).
Likewise, the amount of C[ABD]SL[Eu] was lower than the non-
ABD-containing control in the liver. Since proteins entering
the liver are eliminated by specific receptors and unspecific
phagocytic uptake (Solá and Griebenow, 2011), FcRn recycling
is also here a likely explanation for the difference in deposition
between the construct with and without ABD. While the
difference in kidney deposition between C[ABD]SL[Eu] and the
control became apparent already at the first investigated time
point (144 h), it was surprising that the highest concentrations
of both proteins were reached only after 216 h. This delay in
clearance may be explained by the same reasons as for the
unexpectedly long serum circulation half-life of the CSL[Eu], i.e.,
charge and other physicochemical properties.
Despite the potential benefits of half-life extension strategies
regarding the in vivo efficacy of endolysin-based compounds, it
should not be forgotten that any modification of these enzymes,
be it through genetic engineering or biochemical approaches,
can have a detrimental effect on their antimicrobial activity,
which may outweigh the positive effect of an extended half-life
on the overall efficacy. This may be due to reduced diffusion,
steric hindrance, lower flexibility between individual domains
or unpredictable changes affecting the folding of the molecule.
Reduced enzymatic and antimicrobial activity was also observed
for the C[ABD]S construct compared to the control in this
study. The best way to improve the enzymatic activity is
probably to work further in detail on the positioning of the
ABD to avoid steric hindrance and allow for accurate flexibility
between domains. However, it is encouraging to find that the
ABD-containing construct was still very potent and reduced
S. aureus by 3-logs in human serum within 60 min at the
tested concentrations (compared to 4 logs for the control).
Given this residual activity, our strategy compares favorably
with other half-life extension approaches that lead to complete
inactivation of the PGH (Walsh et al., 2003; Resch et al.,
2011b). A strategy that likely would improve treatment, but
possibly complicate the regulatory process, is to administer a
mix of both highly active wild type endolysin to get high initial
activity and the half-life extended variant to clear any persistent
bacteria.
CONCLUSION
In conclusion, we have shown that fusion of an endolysin
to the ABD represents a promising strategy to extend the
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serum circulation half-life of a modular PGH, while retaining a
considerable level of antimicrobial activity.
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